OBM Genetics

(ISSN 2577-5790)

OBM Genetics is an international Open Access journal published quarterly online by LIDSEN Publishing Inc. It accepts papers addressing basic and medical aspects of genetics and epigenetics and also ethical, legal and social issues. Coverage includes clinical, developmental, diagnostic, evolutionary, genomic, mitochondrial, molecular, oncological, population and reproductive aspects. It publishes research articles, reviews, communications and technical notes, etc. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.

Archiving: full-text archived in CLOCKSS.

Rapid publication: manuscripts are undertaken in 15.0 days from acceptance to publication (median values for papers published in this journal in the second half of 2021, 1-2 days of FREE language polishing time is also included in this period).

Current Issue: 2023  Archive: 2022 2021 2020 2019 2018 2017
Open Access Research Article

Molecular and in Silico Analysis of MEFV Variants in Familial Mediterranean Fever Patients in Southwest Iran

Negar Noorbakhsh 1,2, Mina Zamani 1,3, Alireza Sedaghat 3,4, Jawaher Zeighami 3, Farangis Foroughi Behbahani 3, Sahere Parvas 3, Alihossein Saberi 3,5, Mohammad Hamid 6, Roya Ghanavati 2, Gholamreza Shariati 3,5,*, Hamid Galehdari 1,*

  1. Department of Biology, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran

  2. Behbahan Faculty of Medical Sciences, Behbahan, Iran

  3. Narges Medical Genetics and Prenatal Diagnosis Laboratory, Kianpars, Ahvaz, Iran

  4. Health Research Institute, Diabetes Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

  5. Department of Medical Genetics, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

  6. Department of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran

Correspondences: Gholamreza Shariati and Hamid Galehdari

Academic Editor: Xiangzi Han

Received: October 11, 2022 | Accepted: May 08, 2023 | Published: May 12, 2023

OBM Genetics 2023, Volume 7, Issue 2, doi:10.21926/obm.genet.2302181

Recommended citation: Noorbakhsh N, Zamani M, Sedaghat A, Zeighami J, Foroughi F, Parvas S, Saberi A, Hamid M, Ghanavati R, Shariati G, Galehdari H. Molecular and in Silico Analysis of MEFV Variants in Familial Mediterranean Fever Patients in Southwest Iran. OBM Genetics 2023;7(2): 181; doi:10.21926/obm.genet.2302181.

© 2023 by the authors. This is an open access article distributed under the conditions of the Creative Commons by Attribution License, which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is correctly cited.


Familial Mediterranean Fever (FMF) is classified as an autoinflammatory genetic disease inherited by mutations in MEFV. These mutations can affect the dysregulation of inflammatory processes in the human body and lead to fever and pain in the chest and abdomen. Many known missense mutations in MEFV are linked to FMF disease. Mutations in MEFV in most cases are located on the short arm of chromosome 16 and can impair the function of the pyrin protein. In this research, we aimed to examine the entire exons of MEFV for 13 cases (8 females and 5 males) with FMF diagnosis from Southwest Iran. Hence, we amplified and sequenced the exons of MEFV and then, in-silico analysis of detected changes was applied to estimate the probability of pathogenicity for the identified variants. Finally, we found five single nucleotide substitutions, including M694V (c.2080A>G), R202Q (c.605G>A), E447G (c.1430A>G), E148Q (c.442G>C), and V726A (c.2177T>C), in the under-represented patients. The most frequent mutations in our study were R202Q (38.46%) within exon 2 and M694V (30.7%) within exon 10. Other mutations accounted for a further 23% of the alleles, including E477G (7.6%), E148Q (7.6%), and V726A (7.6%). According to the in-silico analyses, including variation pathogenicity, protein structure, and allele frequency assessments, we concluded that all these variants could be considered in FMF molecular profiling in southwest Iran.


Autoinflammatory disease; familial Mediterranean fever; MEFV mutations; missense mutations 

1. Introduction

Familial Mediterranean Fever (FMF, OMIM# 249100) is a hereditary autoinflammatory disease caused by gain-of-function mutations in MEFV [1]. This gene is located on the 16p13.3 chromosome, comprised of 10 exons with 21600 base pairs which can make a 781-amino acid long protein called pyrin [2,3]. Pyrin is essential in the immune system and regulates inflammation processes by attaching to additional proteins forming the inflammasome complex [4,5]. The MEFV mutations directly affect pyrin protein activity by disrupting the balance between different inflammation factors, which may cause pain and fever in the chest, abdomen, and joints [6]. To date, mutations reported from different populations for FMF include Jewish, Armenian, Turkish, and Arab people with different frequencies [7]. From reported changes in the MEFV, five missense mutations namely E148Q, M694I, M694V, M680I, and V726A count as the most common reported mutations [8,9]. The major site of mutations in exons 10 and 2 has a smaller cluster, while exons 3, 5, and 9 have less frequent variants. Since this disease has a wide range of signs and symptoms, it is necessary to use molecular techniques to help with clinical diagnosis. Hence, in this study, we determined pathogenic variants of MEFV, coupled with bioinformatics analysis, in FMF patients with clinical manifestations of persistent fever and abdominal pain referring to Narges Genetic Laboratory. This study can help with a final diagnosis of MEFV mutation distributions in Iranian patients from southwest of Iran.

2. Materials and Methods

2.1 Editorial Policies and Ethical Considerations

This research study was approved by the Ahvaz Jundishapur University of Medical Sciences Institutional Review. In addition, a declaration of consent was obtained from participants.

2.2 Study Design and Patients

For the current study, the confirmation of FMF diagnosis for the patients referred to Narges Genetic Laboratory in the southwest of Iran using molecular techniques was performed [10]. The inclusive enrolment dates of this study were from July 2013 to June 2022. Moreover, the individual signed information according to the ethical requirements.

2.3 Peripheral Blood Samples

Blood samples (10 ml) were obtained from all enrolled FMF patients and their parents in EDTA tubes.

2.4 Genomic DNA Extraction

Genomic DNA was extracted from the 10 ml peripheral blood samples using the salting-out technique obtained from subjects [11]. Next, the quality and the quantity of the isolated DNA samples were analyzed by gel electrophoresis and Nano-drop (ThermoFisher, Europe).

2.5 Polymerase Chain Reaction

Primer3 tool was utilized to design primers for all exons of MEFV [12]. For PCR, Master Mix (Ampliqon Denmark) was used. The first step was performed at 93°C for 5 min as initial denaturation, then 35 cycles of 93°C for 1 min, annealing and extension steps at 60°C for 30 sec and 72°C for 30 sec respectively. Post-PCR final incubation step of 72°C for 3 min as a final extension. The details of primers are provided in Table 1.

Table 1 Primer sequences used for PCR and Sanger sequencing.

2.6 Gene Sequencing

Mutations in MEFV were examined in DNA amplicons using Applied Biosystems 3700 DNA analyzer (sequencer). Results of the Sanger sequencing were evaluated using Chromas LITE2.1.1, and the BLASTN software.

2.7 In-Silico Analysis of Variants

There are many tools for analyzing the pathogenicity potent and structure of variants. In the present study, we used some of these tools for the evaluation of disease-causing potentiality
of the variants. In the first step, the reference coding DNA and protein sequence of human MEFV wild-type were collected from the Ensembl genome (gene bank transcript ID ENST00000219596, NM_000243) database (https://asia.ensembl.org/index.html). We implemented the program Predict SNP which significantly enhanced prediction performance and simultaneously returned results for all mutations [13]. The Mutation Taster2 can estimate the functional consequence of amino acid residue substitutions, intronic alterations, indel mutations, and variants spanning introns-exon borders [14]. Moreover, SNPs & GO are suitable for predicting whether a specific variation can be categorized as disease-related or neutral. This tool uses the protein function to predict the pathogenicity of missense mutations [15]. Meta-SNP is another method for detecting synonymous SNVs for disease-associated SNVs [16]. SNAP2 is a neural network-based classifier for screening and predicting the functional effects of sequence variants [17]. Mutation Assessor Web server indicates variants to have a low, medium, and high probability of affecting protein function or being natural [18]. SIFT is a computer algorithm that can predict the effect of amino acid substitution on protein function [19].

2.8 Stability Assessment

The predicting protein stability upon mutation of amino acids is evaluated by I-Mutant [20].

2.9 Structural Analysis

Knowing the 3D structure of a protein provides insight into the mechanism of that protein. HOPE is a powerful program that assesses the function and structure of point mutations [21]. This tool predicts the effects of a mutation on protein structure and function by merging all collected data with known properties of the mutated and wild-type amino acids, such as charge, size, and hydrophobicity value [22].

2.10 Secondary Structure Analysis

YASARA is a molecular modeling program that visualizes large proteins [23]. In this regard, mutant and wild-type protein analysis were done with YASARA version 15.6.21. This research study was approved by the Ahvaz Jundishapur University of Medical Sciences Institutional Review Boards. For genetic analyses, informed consent was waived. All experiments were performed in accordance with relevant guidelines and regulations. All patients provided written informed consent to participate in the study.

3. Results

A total of 13 individuals with FMF (8 Females and 5 Males), from the Southwest of Iran with various ethnicities, including Lor, Fars, and Arab, participated in this research (Table 2). Five mutations in MEFV were recognized in enrolled patients (Table 3). In Figure 1, we summed up observed genetic variations in the MEFV in cases with FMF from southwest Iran.

Table 2 A brief of the description of 13 affected individuals.

Table 3 All detected variations in the enrolled FMF in the following research.

Click to view original image

Figure 1 Schematic diagram of the MEFV gene depicting the location of the under study variants in MEFV Gene.

3.1 Pathogenicity Prediction of Variants

Various Bioinformatics tools were used to predict the disease-causing potentiality of mutations in the MEFV of FMF patients. The pathogenic prediction of the variants has been summarized in Table 4. E477G is categorized as disease-causing according to Predict SNP, Meta-SNP, SNP&GO, Mutation Assessor, SIFT and Mutation Taster. According to Predict SNP and Mutation assessor and SIFT E148Q is considered a pathogenic mutation. Mutation Taster V726A was shown as a disease-causing mutation; however, Predict SNP, Meta-SNP, SNP&GO, Mutation Assessor, SIFT and SNAP2 considered V726A as a neutral mutation. Regarding M694V and R202Q variants, SNAP2 and mutation taster suggested they are pathogenic, while Predict SNP, Meta-SNP, SNP&GO and Mutation Assessor showed that they are neural.

Table 4 The results of the pathogenicity prediction of point mutation of MEFV gene.

3.2 Stability Assessment

The protein stability of all variants in the conditions 25°C and pH 7 was assessed, and the data showed that stability of proteins significantly decrease for M694V, E477G, R202Q, E148Q, and V726A variants [Table 5].

Table 5 The result of protein stability of variants by I-Mutant.

3.3 Structural Analysis

Based on the Hope results [Figure 2], we provided a summary for evaluating the structural characteristics of variants: M694V can disturb the protein domain and abolish its function because of the different amino acid properties. In comparison to wild-type residue the mutant residue is smaller in size. This mutation is located in a domain important for the binding of other molecules and can cause a possible loss of external interaction [22]. R202Q changes the positive charge of the wild-type into the neutral charge in mutant residue. In addition, the mutant residue is smaller than the wild-type residue, which can cause loss of interactions with other molecules and differences in size. V726A variant in mutant and wild-type amino acids differs in size (mutant residue is smaller). Moreover, because of the changes in the properties of amino acids, this mutation can distribute the protein domain and abolish its function. E148Q variant can change the negative charge of the wild-type residue to a neutral charge in the mutant residue. This alteration causes charge difference and leads to loss of interaction with other molecules or residues. E477G can change the negative charge of the wild-type variant into the neutral charge of mutant residue, which is more hydrophobic than wild-type amino acid. Moreover, since the mutation is located within a stretch of residues (special region), it can affect amino acid properties (Glycin is very flexible), and consequently can disturb the region and function of mutant protein [22].

Click to view original image

Figure 2 shows the main (left) schematic structures and the altered (right) amino acid. The backbone is colored red (similar for each amino acid residue), while the side chain is colored black (unique for each amino acid residue).

4. Discussion

FMF is an autoinflammatory disorder with worldwide affected individuals (about 120,000 people), and with the highest frequency among ethnic communities of the eastern Mediterranean, such as Turks, Jews, Armenian, and Arabs (with the highest number in Turkey) [24]. Mutations in the MFEV gene cause this autosomal recessive disorder [25,26]. From the molecular genetic view, it is vital to predicting precisely the connection between the pathogenicity of the changes on the DNA level and clinical consequences of observed mutations; for this purpose, computational tools are employed.

In silico approaches are less time-consuming, cost-effective for identifying candidate mutations, and suitable for genetic studies [3]. Over 333 mutations have been found in MEFV related to FMF disease, mainly in exons 2 and 10 [Figure 1] of MEFV with different frequencies among various ethnic groups and people [26,27,28]. In regional studies, the most common variants are R202Q, M694V, E148Q, M680I, V726A and M694I [27,29]. The E148Q and M694V are the most changes, especially in Turkey, Israel, North African Jews, and Armenians [30,31,32]. In the studies of Celep et al. in 2019, the R202Q variant was the most frequent mutation in Northern Anatolia [33]. In Iran, a total of 38 various mutations in the MEFV gene have been recognized, and M694V, E148Q, V726A, M680I, and M694I were the most common among Iranian FMF patients. Moreover, in the southwest of Iran, M694V, V726A, and M694I are the most common types of mutations [34]. In the present study, entire exons of the MEFV gene were sequenced for 13 patients suffering from FMF in southwest of Iran. All of the patients in our study were diagnosed with FMF with recurrent episodes of fever associated with abdominal pain. The most prevalent mutations in our study were R202Q, followed by M694V. The use of bioinformatic tools performed the prediction of the potential pathogenicity of these variations. To examine the stability of proteins we used I-Mutant3 which showed that the stability of proteins significantly decreases in V726A, M694V, and E477G variants. For structural analysis of proteins of mutations, we used the HOPE® tool. Each amino acid indeed has specific biochemical and biophysical characteristics and amino acid change can alter the structure and function of their proteins. Based on Hope analysis all mentioned variants can disturb some intra and inter action of proteins. Although R202Q and E148Q are suggested as polymorphism, changes in the positive charge of the wild-type into the neutral charge in mutant residue in R202Q and negative charge of the wild-type into the neutral charge in mutant residue in E148Q can reduce the interactions with other molecules. Finally, we suggest that all mentioned variants in this study are probably deleterious and can be used to diagnose FMF.

5. Limitation

This study has investigated the molecular analysis of MEFV variants in southwest Iran. Our results were analyzed from bioinformatics to gain a deeper understanding of variants. However, the scope and findings of our study were limited by the number of 13 FMF patients who chose to seek clinical testing and consultation from our qualified healthcare professional.


The authors acknowledge the collaboration Narges Genetic Laboratory team as well as the patients and their families who provided specimens for this study.

Author Contributions

HG and MZ conceptualized the study; NN collected the Data, wrote the original draft, prepared Figures 1 and 2; JZ, FF, and SP were responsible for PCR and Sanger sequencing; H.G, MH, AS, and GS provided supervision; MZ & HG & RG reviewed the original draft.

Competing Interests

The authors declare that they have no competing interests.


  1. Çapraz M, Düz ME. R202Q prevalence in clinically diagnosed familial Mediterranean fever patients: 9 years of data analysis from 1570 patients living Central Black Sea Region, Turkey. Ir J Med Sci. 2022; 1-6. doi: 10.1007/s11845-022-03233-1. [CrossRef]
  2. Schnappauf O, Chae JJ, Kastner DL, Aksentijevich I. The pyrin inflammasome in health and disease. Front Immunol. 2019; 10: 1745. [CrossRef]
  3. Mustafa MI, Abdelhameed TA, Abdelrhman FA, Osman SA, Hassan MA. Novel deleterious nsSNPs within MEFV gene that could be used as diagnostic markers to predict hereditary familial Mediterranean fever: Using bioinformatics analysis. Adv Bioinformatics. 2019; 2019: 1651587. [CrossRef]
  4. Chong WC, Shastri MD, Peterson GM, Patel RP, Pathinayake PS, Dua K, et al. The complex interplay between endoplasmic reticulum stress and the NLRP3 inflammasome: A potential therapeutic target for inflammatory disorders. Clin Transl Immunol. 2021; 10: e1247. [CrossRef]
  5. Kırnaz B, Gezgin Y, Berdeli A. MEFV gene allele frequency and genotype distribution in 3230 patients’ analyses by next generation sequencing methods. Gene. 2022; 827: 146447. [CrossRef]
  6. Simon A, van der Meer JW, Drenth JP. Familial Mediterranean fever—a not so unusual cause of abdominal pain. Best Pract Res Clin Gastroenterol. 2005; 19: 199-213. [CrossRef]
  7. Dundar M, Kiraz A, Emirogullari EF, Saatci Ç, Taheri S, Baskol M, et al. A molecular analysis of familial Mediterranean fever disease in a cohort of Turkish patients. Ann Saudi Med. 2012; 32: 343-348. [CrossRef]
  8. Kilic A, Varkal MA, Durmus MS, Yildiz I, Yıldırım ZN, Turunc G, et al. Relationship between clinical findings and genetic mutations in patients with familial Mediterranean fever. Pediatric Rheumatol. 2015; 13: 59. [CrossRef]
  9. Fujikura K. Global epidemiology of familial Mediterranean fever mutations using population exome sequences. Mol Genet Genomic Med. 2015; 3: 272-282. [CrossRef]
  10. Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 1997; 40: 1879-1885. [CrossRef]
  11. Farahzadi HN, Akbari MT, Shiari R, Karizi SZ, Farivar S. Spectrum of Mutations of familial Mediterranean fever gene by whole sequencing method in Iranian patients. J Hum Genet Genomics. 2019; 3: e111252.
  12. Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, et al. Primer3—new capabilities and interfaces. Nucleic Acids Res. 2012; 40: e115. [CrossRef]
  13. Bendl J, Stourac J, Salanda O, Pavelka A, Wieben ED, Zendulka J, et al. PredictSNP: Robust and accurate consensus classifier for prediction of disease-related mutations. PLoS Comput Biol. 2014; 10: e1003440. [CrossRef]
  14. Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: Mutation prediction for the deep-sequencing age. Nat Methods. 2014; 11: 361-362. [CrossRef]
  15. Thusberg J, Olatubosun A, Vihinen M. Performance of mutation pathogenicity prediction methods on missense variants. Hum Mutat. 2011; 32: 358-368. [CrossRef]
  16. Pei J, Grishin NV. AL2CO: Calculation of positional conservation in a protein sequence alignment. Bioinformatics. 2001; 17: 700-712. [CrossRef]
  17. Hecht M, Bromberg Y, Rost B. Better prediction of functional effects for sequence variants. BMC Genom. 2015; 16: S1. [CrossRef]
  18. Gnad F, Baucom A, Mukhyala K, Manning G, Zhang Z. Assessment of computational methods for predicting the effects of missense mutations in human cancers. BMC Genom. 2013; 14: S7. [CrossRef]
  19. Sim NL, Kumar P, Hu J, Henikoff S, Schneider G, Ng PC. SIFT web server: Predicting effects of amino acid substitutions on proteins. Nucleic Acids Res. 2012; 40: W452-W457. [CrossRef]
  20. Capriotti E, Calabrese R, Casadio R. Predicting the insurgence of human genetic diseases associated to single point protein mutations with support vector machines and evolutionary information. Bioinformatics. 2006; 22: 2729-2734. [CrossRef]
  21. Kumar R, Jayaraman M, Ramadas K, Chandrasekaran A. Insight into the structural and functional analysis of the impact of missense mutation on cytochrome P450 oxidoreductase. J Mol Graph Model. 2020; 100: 107708. [CrossRef]
  22. Venselaar H, Te Beek TA, Kuipers RK, Hekkelman ML, Vriend G. Protein structure analysis of mutations causing inheritable diseases. An e-Science approach with life scientist friendly interfaces. BMC Bioinform. 2010; 11: 548. [CrossRef]
  23. Krieger E, Vriend G. YASARA View—molecular graphics for all devices—from smartphones to workstations. Bioinformatics. 2014; 30: 2981-2982. [CrossRef]
  24. Padeh S, Bilginer Y, Ozen S. Familial Mediterranean fever. In: Textbook of autoinflammation. Berlin: Springer; 2019. pp. 293-313. [CrossRef]
  25. Ozdogan H, Ugurlu S. Familial Mediterranean fever. La Presse Médicale. 2019; 48: e61-e76. [CrossRef]
  26. Moradian MM, Babikyan D, Banoian D, Hayrapetyan H, Manvelyan H, Avanesian N, et al. Comprehensive analysis of mutations in the MEFV gene reveal that the location and not the substitution type determines symptom severity in FMF. Mol Genet Genomic Med. 2017; 5: 742-750. [CrossRef]
  27. Gumus E. The frequency of MEFV gene mutations and genotypes in Sanliurfa province, South-Eastern region of Turkey, after the Syrian Civil War by using next generation sequencing and report of a novel exon 4 mutation (I423T). J Clin Med. 2018; 7: 105. [CrossRef]
  28. Mansour AR, El-Shayeb A, El Habachi N, Khodair MA, Elwazzan D, Abdeen N, et al. Molecular patterns of MEFV gene mutations in Egyptian patients with familial Mediterranean fever: A retrospective cohort study. Int J Inflam. 2019; 2019: 2578760. [CrossRef]
  29. Kilinc M, Ganiyusufoglu E, Sager H, Celik A, Olgar S, Cetin GY, et al. The report of sequence analysis on familial Mediterranean fever gene (MEFV) in South-eastern Mediterranean region (Kahramanmaraş) of Turkey. Rheumatol Int. 2016; 36: 25-31. [CrossRef]
  30. Özen S, Batu ED, Demir S. Familial Mediterranean fever: Recent developments in pathogenesis and new recommendations for management. Front Immunol. 2017; 8: 253. [CrossRef]
  31. The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell. 1997; 90: 797-807. [CrossRef]
  32. Haghighat M, Moghtaderi M, Farjadian S. Genetic analysis of southwestern Iranian patients with familial Mediterranean fever. Rep Biochem Mol Biol. 2017; 5: 117.
  33. Celep G, Durmaz ZH, Erdogan Y, Akpinar S, Kaya SA, Guckan R. The spectrum of MEFV gene mutations and genotypes in the Middle Northern Region of Turkey. Eurasian J Med. 2019; 51: 252. [CrossRef]
  34. Alibakhshi R, Mohammadi A, Ghadiri K, Khamooshian S, Kazeminia M, Moradi KJEJoMHG. Spectrum of MEFV gene mutations in 4,256 familial Mediterranean fever patients from Iran: A comprehensive systematic review. Egypt J Medical Hum Genet. 2022; 23: 5. [CrossRef]
Download PDF Download Citation
0 0